Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Cancer"
DOI: 10.1002/ijc.31647
Abstract: Higher lignan exposure has been associated with lower all‐cause mortality (ACM) and breast cancer‐specific mortality (BCSM) for postmenopausal breast cancer patients. However, the biological mechanisms underpinning these associations are still unclear. We investigated for the… read more here.
Keywords: cancer; inflammatory markers; postmenopausal breast; breast cancer ... See more keywords
Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Survivorship"
DOI: 10.1007/s11764-019-00782-w
Abstract: Among a cohort of postmenopausal breast cancer survivors, we aimed to compare the risk of dementia associated with aromatase inhibitor (AI) therapy versus tamoxifen. Using UK primary care electronic health records, we identified 14,214 postmenopausal… read more here.
Keywords: risk; dementia; breast cancer; cancer ... See more keywords
Prognostic associations of circulating phytoestrogens and biomarker changes in long-term survivors of postmenopausal breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Nutrition and Cancer"
DOI: 10.1080/01635581.2019.1672762
Abstract: Abstract Lignans are associated with improved postmenopausal breast cancer (BC) survival, but whether these associations, particularly with enterolactone (major lignan metabolite), persist over time is unclear. Little is known about other phytoestrogens on prognosis in… read more here.
Keywords: term; long term; breast cancer; term survivors ... See more keywords
High risk for cardiovascular disease in postmenopausal breast cancer survivors.
Sign Up to like & getrecommendations! Published in 2019 at "Menopause"
DOI: 10.1097/gme.0000000000001348
Abstract: OBJECTIVE Breast cancer patients have a higher mortality risk of cardiovascular disease (CVD) than women from the general population. CVD risk may increase significantly in postmenopausal women with early-stage breast cancer. The aim of this… read more here.
Keywords: cancer survivors; cancer; risk; breast cancer ... See more keywords
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
Sign Up to like & getrecommendations! Published in 2023 at "EMBO Molecular Medicine"
DOI: 10.15252/emmm.202216715
Abstract: Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and… read more here.
Keywords: breast; postmenopausal breast; poor prognosis; breast cancer ... See more keywords